Immutep Advances to Phase III with Key Approvals and Promising Trial Results

Immutep ( (IMMP) ) has provided an update.

Immutep Limited announced significant advancements in its clinical trials and research efforts, marking a transition to a Phase III biotech company. The company received its first regulatory approval for the pivotal TACTI-004 Phase III trial for non-small cell lung cancer in December 2024, and reported promising results from various other trials, including INSIGHT-003 and EFTISARC-NEO, demonstrating improved survival rates and tumour responses. Additionally, Immutep’s collaboration with Monash University led to a groundbreaking publication in Science Immunology, enhancing the understanding of LAG-3 interactions and supporting further therapeutic development.

More about Immutep

Immutep Limited is a clinical-stage biotechnology company focused on the development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company is based in Sydney, Australia, and is listed on both the ASX and NASDAQ.

YTD Price Performance: -5.43%

Average Trading Volume: 122,678

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $307.2M

Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.